Mitazalimab

米佐利单抗

Report date: 2026/05/07 20:00:36

Base Information

Drug NameMitazalimab
Drug Alias NameVanalimabADC-1013JNJ-7107JNJ-64457107
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsBiliary Tract Neoplasms +[6
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[9
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlligator Bioscience Ab
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsBiliary Tract Neoplasms +[5
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank